| US9228186B2 (en) | 2002-11-14 | 2016-01-05 | Thermo Fisher Scientific Inc. | Methods and compositions for selecting siRNA of improved functionality |
| EP2636739B1 (en) | 2004-03-12 | 2014-12-10 | Alnylam Pharmaceuticals Inc. | iRNA agents targeting VEGF |
| ATE536418T1 (en) | 2004-06-07 | 2011-12-15 | Protiva Biotherapeutics Inc | LIPID ENCAPSULATED INTERFERENCE RNA |
| CA2651839C (en) | 2006-05-11 | 2016-02-09 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of the pcsk9 gene |
| US8546554B2 (en) | 2008-09-25 | 2013-10-01 | Alnylam Pharmaceuticals, Inc. | Lipid formulated compositions and methods for inhibiting expression of Serum Amyloid A gene |
| PL2350043T3 (en) | 2008-10-09 | 2014-09-30 | Tekmira Pharmaceuticals Corp | Improved amino lipids and methods for the delivery of nucleic acids |
| ES2656516T3 (en) | 2008-10-20 | 2018-02-27 | Alnylam Pharmaceuticals, Inc. | Compositions and methods to inhibit the expression of transthyretin |
| CN105709229B (en)* | 2008-11-10 | 2020-07-28 | 阿布特斯生物制药公司 | Novel lipids and compositions for delivery of therapeutic agents |
| CA2746514C (en) | 2008-12-10 | 2018-11-27 | Alnylam Pharmaceuticals, Inc. | Gnaq targeted dsrna compositions and methods for inhibiting expression |
| CA2760706C (en)* | 2009-05-05 | 2019-08-06 | Alnylam Pharmaceuticals, Inc. | Methods of delivering oligonucleotides to immune cells |
| KR102374518B1 (en)* | 2009-06-10 | 2022-03-16 | 알닐람 파마슈티칼스 인코포레이티드 | Improved lipid formulation |
| US9051567B2 (en) | 2009-06-15 | 2015-06-09 | Tekmira Pharmaceuticals Corporation | Methods for increasing efficacy of lipid formulated siRNA |
| WO2010148013A2 (en) | 2009-06-15 | 2010-12-23 | Alnylam Pharmaceuticals, Inc. | Lipid formulated dsrna targeting the pcsk9 gene |
| US8569256B2 (en) | 2009-07-01 | 2013-10-29 | Protiva Biotherapeutics, Inc. | Cationic lipids and methods for the delivery of therapeutic agents |
| US9018187B2 (en) | 2009-07-01 | 2015-04-28 | Protiva Biotherapeutics, Inc. | Cationic lipids and methods for the delivery of therapeutic agents |
| US8236943B2 (en) | 2009-07-01 | 2012-08-07 | Protiva Biotherapeutics, Inc. | Compositions and methods for silencing apolipoprotein B |
| CA2767127A1 (en) | 2009-07-01 | 2011-01-06 | Protiva Biotherapeutics, Inc. | Novel lipid formulations for delivery of therapeutic agents to solid tumors |
| WO2011011447A1 (en) | 2009-07-20 | 2011-01-27 | Protiva Biotherapeutics, Inc. | Compositions and methods for silencing ebola virus gene expression |
| EP2464336A4 (en)* | 2009-08-14 | 2013-11-20 | Alnylam Pharmaceuticals Inc | Lipid formulated compositions and methods for inhibiting expression of a gene from the ebola virus |
| WO2011022460A1 (en) | 2009-08-20 | 2011-02-24 | Merck Sharp & Dohme Corp. | Novel cationic lipids with various head groups for oligonucleotide delivery |
| US9187746B2 (en) | 2009-09-22 | 2015-11-17 | Alnylam Pharmaceuticals, Inc. | Dual targeting siRNA agents |
| WO2011038160A2 (en) | 2009-09-23 | 2011-03-31 | Protiva Biotherapeutics, Inc. | Compositions and methods for silencing genes expressed in cancer |
| US9101643B2 (en) | 2009-11-03 | 2015-08-11 | Alnylam Pharmaceuticals, Inc. | Lipid formulated compositions and methods for inhibiting expression of transthyretin (TTR) |
| CN102712935B (en) | 2009-11-04 | 2017-04-26 | 不列颠哥伦比亚大学 | Nucleic acid-containing lipid particles and related methods |
| HUE038039T2 (en) | 2009-12-01 | 2018-09-28 | Translate Bio Inc | Delivery of mrna for the augmentation of proteins and enzymes in human genetic diseases |
| AU2010328336B2 (en) | 2009-12-07 | 2017-03-02 | Arbutus Biopharma Corporation | Compositions for nucleic acid delivery |
| AU2010330814B2 (en)* | 2009-12-18 | 2017-01-12 | Acuitas Therapeutics Inc. | Methods and compositions for delivery of nucleic acids |
| CN102905763B (en) | 2009-12-23 | 2015-06-17 | 诺华股份有限公司 | Lipids, lipid compositions, and methods of using them |
| EP2558074B1 (en) | 2010-04-08 | 2018-06-06 | The Trustees of Princeton University | Preparation of lipid nanoparticles |
| WO2011133871A2 (en) | 2010-04-22 | 2011-10-27 | Alnylam Pharmaceuticals, Inc. | 5'-end derivatives |
| WO2011136369A1 (en)* | 2010-04-28 | 2011-11-03 | 協和発酵キリン株式会社 | Cationic lipid |
| KR101773643B1 (en) | 2010-04-28 | 2017-08-31 | 교와 핫꼬 기린 가부시키가이샤 | Cationic lipid |
| US9254327B2 (en)* | 2010-05-10 | 2016-02-09 | Alnylam Pharmaceuticals, Inc. | Methods and compositions for delivery of active agents |
| WO2011141705A1 (en) | 2010-05-12 | 2011-11-17 | Protiva Biotherapeutics, Inc. | Novel cationic lipids and methods of use thereof |
| WO2011141703A1 (en)* | 2010-05-12 | 2011-11-17 | Protiva Biotherapeutics Inc. | Compositions and methods for silencing apolipoprotein b |
| US10077232B2 (en) | 2010-05-12 | 2018-09-18 | Arbutus Biopharma Corporation | Cyclic cationic lipids and methods of use |
| WO2011149733A2 (en) | 2010-05-24 | 2011-12-01 | Merck Sharp & Dohme Corp. | Novel amino alcohol cationic lipids for oligonucleotide delivery |
| KR101967411B1 (en)* | 2010-06-03 | 2019-04-10 | 알닐람 파마슈티칼스 인코포레이티드 | Biodegradable lipids for the delivery of active agents |
| CA2804396C (en) | 2010-07-06 | 2021-06-29 | Novartis Ag | Liposomes with lipids having an advantageous pka-value for rna delivery |
| PT3243526T (en) | 2010-07-06 | 2020-03-04 | Glaxosmithkline Biologicals Sa | DISTRIBUTION OF RNA TO DISPOLISH MULTIPLE IMMUNITY ROUTES |
| DK2591114T3 (en) | 2010-07-06 | 2016-08-29 | Glaxosmithkline Biologicals Sa | Immunization of large mammals with low doses of RNA |
| US20130323269A1 (en)* | 2010-07-30 | 2013-12-05 | Muthiah Manoharan | Methods and compositions for delivery of active agents |
| US20130202652A1 (en) | 2010-07-30 | 2013-08-08 | Alnylam Pharmaceuticals, Inc. | Methods and compositions for delivery of active agents |
| EP2601293B1 (en)* | 2010-08-02 | 2017-12-06 | Sirna Therapeutics, Inc. | RNA INTERFERENCE MEDIATED INHIBITION OF CATENIN (CADHERIN-ASSOCIATED PROTEIN), BETA 1 (CTNNB1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
| CA2807552A1 (en) | 2010-08-06 | 2012-02-09 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| CA2807307C (en) | 2010-08-17 | 2021-02-09 | Merck Sharp & Dohme Corp. | Rna interference mediated inhibition of hepatitis b virus (hbv) gene expression using short interfering nucleic acid (sina) |
| EP2609106A4 (en) | 2010-08-26 | 2014-03-19 | Merck Sharp & Dohme | RNA INTERFERENCE-MEDIATED INHIBITION OF EXPRESSION OF PHD2 GENE (PROLYL HYDROXYLASE DOMAIN 2) USING SMALL INTERFERING NUCLEIC ACID (PANI) |
| RS63329B1 (en) | 2010-08-31 | 2022-07-29 | Glaxosmithkline Biologicals Sa | Pegylated liposomes for delivery of immunogen-encoding rna |
| KR20130100278A (en) | 2010-08-31 | 2013-09-10 | 머크 샤프 앤드 돔 코포레이션 | Novel single chemical entities and methods for delivery of oligonucleotides |
| US8466122B2 (en) | 2010-09-17 | 2013-06-18 | Protiva Biotherapeutics, Inc. | Trialkyl cationic lipids and methods of use thereof |
| EP3144015B1 (en) | 2010-09-20 | 2021-06-02 | Sirna Therapeutics, Inc. | Low molecular weight cationic lipids for oligonucleotide delivery |
| WO2012044638A1 (en) | 2010-09-30 | 2012-04-05 | Merck Sharp & Dohme Corp. | Low molecular weight cationic lipids for oligonucleotide delivery |
| PL4108671T3 (en) | 2010-10-01 | 2025-02-24 | Modernatx, Inc. | MODIFIED NUCLEOSIDES, NUCLEOTIDES AND NUCLEIC ACIDS AND THEIR USES |
| ES2716243T3 (en) | 2010-10-11 | 2019-06-11 | Glaxosmithkline Biologicals Sa | Antigen Supply Platforms |
| CA2813024A1 (en)* | 2010-10-21 | 2012-04-26 | Merck Sharp & Dohme Corp. | Novel low molecular weight cationic lipids for oligonucleotide delivery |
| EP3766975A1 (en) | 2010-10-29 | 2021-01-20 | Sirna Therapeutics, Inc. | Rna interference mediated inhibition of gene expression using short interfering nucleic acid (sina) |
| US9067882B2 (en) | 2010-11-05 | 2015-06-30 | Sirna Therapeutics, Inc. | Low molecular weight cyclic amine containing cationic lipids for oligonucleotide delivery |
| BR122022001262B1 (en)* | 2010-11-15 | 2022-09-27 | Life Technologies Corporation | TRANSFECTION COMPOUNDS CONTAINING AMINE AND TRANSFECTION COMPLEX |
| WO2012075040A2 (en) | 2010-11-30 | 2012-06-07 | Shire Human Genetic Therapies, Inc. | mRNA FOR USE IN TREATMENT OF HUMAN GENETIC DISEASES |
| IT1404011B1 (en)* | 2010-12-03 | 2013-11-08 | Uni Degli Studi Magna Graecia Di Catanzaro | CONJUGATED NANOVECTOR WITH TSH FOR TREATMENT OF THYROID CANCER |
| DK2663548T3 (en) | 2011-01-11 | 2017-07-24 | Alnylam Pharmaceuticals Inc | PEGYLED LIPIDS AND THEIR USE FOR PHARMACEUTICAL SUPPLY |
| DE12722942T1 (en) | 2011-03-31 | 2021-09-30 | Modernatx, Inc. | RELEASE AND FORMULATION OF MANIPULATED NUCLEIC ACIDS |
| EA039892B1 (en)* | 2011-05-23 | 2022-03-24 | Элнилэм Фармасьютикалз, Инк. | Biodegradable lipids for the delivery of active agents |
| DK3336082T3 (en) | 2011-06-08 | 2020-04-27 | Translate Bio Inc | SPLITLY LIPIDS |
| PL2717893T3 (en) | 2011-06-08 | 2019-12-31 | Translate Bio, Inc. | Lipid nanoparticle compositions and methods for mRNA delivery |
| KR102540778B1 (en) | 2011-06-21 | 2023-06-07 | 알닐람 파마슈티칼스 인코포레이티드 | Compositions and methods for inhibition of expression of apolipoprotein c-iii(apoc3) genes |
| US9068184B2 (en) | 2011-06-21 | 2015-06-30 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibition of expression of protein C (PROC) genes |
| WO2013006838A1 (en) | 2011-07-06 | 2013-01-10 | Novartis Ag | Immunogenic combination compositions and uses thereof |
| EP3640332A1 (en) | 2011-08-29 | 2020-04-22 | Ionis Pharmaceuticals, Inc. | Oligomer-conjugate complexes and their use |
| EP2750712A2 (en)* | 2011-08-31 | 2014-07-09 | Mallinckrodt LLC | Nanoparticle peg modification with h-phosphonates |
| US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| AU2012315965A1 (en) | 2011-09-27 | 2014-04-03 | Alnylam Pharmaceuticals, Inc. | Di-aliphatic substituted PEGylated lipids |
| KR102014061B1 (en) | 2011-10-03 | 2019-08-28 | 모더나 세라퓨틱스, 인코포레이티드 | Modified nucleosides, nucleotides, and nucleic acids, and uses thereof |
| ES2745373T3 (en)* | 2011-10-18 | 2020-03-02 | Dicerna Pharmaceuticals Inc | Cationic amine lipids and their use |
| EP2594575A1 (en)* | 2011-11-15 | 2013-05-22 | Université de Strasbourg | Mannosylated compounds useful for the prevention and the treatment of infectious diseases |
| SMT202000308T1 (en) | 2011-11-18 | 2020-07-08 | Alnylam Pharmaceuticals Inc | Rnai agents, compositions and methods of use thereof for treating transthyretin (ttr) associated diseases |
| WO2013073480A1 (en) | 2011-11-18 | 2013-05-23 | 日油株式会社 | Cationic lipid having improved intracellular kinetics |
| US20140308304A1 (en) | 2011-12-07 | 2014-10-16 | Alnylam Pharmaceuticals, Inc. | Lipids for the delivery of active agents |
| JP6305344B2 (en) | 2011-12-07 | 2018-04-04 | アルニラム・ファーマシューティカルズ・インコーポレーテッド | Biodegradable lipids for delivery of active agents |
| US9463247B2 (en)* | 2011-12-07 | 2016-10-11 | Alnylam Pharmaceuticals, Inc. | Branched alkyl and cycloalkyl terminated biodegradable lipids for the delivery of active agents |
| JP2015502365A (en) | 2011-12-12 | 2015-01-22 | オンコイミューニン，インコーポレイティド | In vivo delivery of oligonucleotides |
| CA3018046A1 (en) | 2011-12-16 | 2013-06-20 | Moderna Therapeutics, Inc. | Modified nucleoside, nucleotide, and nucleic acid compositions |
| US9352042B2 (en)* | 2012-02-24 | 2016-05-31 | Protiva Biotherapeutics, Inc. | Trialkyl cationic lipids and methods of use thereof |
| US8546617B1 (en) | 2012-03-23 | 2013-10-01 | Empire Technology Development Llc | Dioxaborinanes and uses thereof |
| WO2013149141A1 (en) | 2012-03-29 | 2013-10-03 | Shire Human Genetic Therapies, Inc. | Lipid-derived neutral nanoparticles |
| HK1206645A1 (en) | 2012-03-29 | 2016-01-15 | Shire Human Genetic Therapies, Inc. | Ionizable cationic lipids |
| US10501513B2 (en) | 2012-04-02 | 2019-12-10 | Modernatx, Inc. | Modified polynucleotides for the production of oncology-related proteins and peptides |
| US9303079B2 (en) | 2012-04-02 | 2016-04-05 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
| US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
| HK1206612A1 (en)* | 2012-04-02 | 2016-01-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of secreted proteins |
| US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
| HK1206636A1 (en) | 2012-04-02 | 2016-01-15 | Modernatx, Inc. | Modified polynucleotides for the production of oncology-related proteins and peptides |
| AU2013249548A1 (en) | 2012-04-19 | 2014-11-06 | Sirna Therapeutics, Inc. | Novel diester and triester based low molecular weight, biodegradable cationic lipids for oligonucleotide delivery |
| US9255154B2 (en) | 2012-05-08 | 2016-02-09 | Alderbio Holdings, Llc | Anti-PCSK9 antibodies and use thereof |
| JP6561378B2 (en) | 2012-06-08 | 2019-08-21 | トランスレイト バイオ， インコーポレイテッド | Transpulmonary delivery of mRNA to non-pulmonary target cells |
| WO2013185067A1 (en) | 2012-06-08 | 2013-12-12 | Shire Human Genetic Therapies, Inc. | Nuclease resistant polynucleotides and uses thereof |
| US9415109B2 (en) | 2012-07-06 | 2016-08-16 | Alnylam Pharmaceuticals, Inc. | Stable non-aggregating nucleic acid lipid particle formulations |
| TW201726599A (en) | 2012-07-06 | 2017-08-01 | 協和醱酵麒麟有限公司 | Cationic lipid |
| US9120938B2 (en) | 2012-07-31 | 2015-09-01 | Empire Technology Development Llc | Polymerizable organoboron alkyd resin anti fouling coatings |
| WO2014028429A2 (en) | 2012-08-14 | 2014-02-20 | Moderna Therapeutics, Inc. | Enzymes and polymerases for the synthesis of rna |
| SMT202200337T1 (en) | 2012-11-26 | 2022-09-14 | Modernatx Inc | Terminally modified rna |
| EA030650B1 (en)* | 2013-03-08 | 2018-09-28 | Новартис Аг | Lipids and lipid compositions for the delivery of active agents |
| AU2014236396A1 (en) | 2013-03-14 | 2015-08-13 | Shire Human Genetic Therapies, Inc. | Methods for purification of messenger RNA |
| IL290953B2 (en) | 2013-03-14 | 2024-01-01 | Ethris Gmbh | Cftr mrna compositions and related methods and uses |
| MX2015011947A (en) | 2013-03-14 | 2015-12-01 | Shire Human Genetic Therapies | Methods and compositions for delivering mrna coded antibodies. |
| EP2971010B1 (en) | 2013-03-14 | 2020-06-10 | ModernaTX, Inc. | Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions |
| HUE071526T2 (en) | 2013-03-15 | 2025-09-28 | Translate Bio Inc | Synergistic enhancement of the delivery of nucleic acids via blended formulations |
| WO2014144767A1 (en) | 2013-03-15 | 2014-09-18 | Moderna Therapeutics, Inc. | Ion exchange purification of mrna |
| EP4279610A3 (en) | 2013-03-15 | 2024-01-03 | ModernaTX, Inc. | Ribonucleic acid purification |
| US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
| CA2906732C (en) | 2013-03-15 | 2023-08-08 | The University Of British Columbia | Lipid nanoparticles for transfection and related methods |
| BR112015027321A8 (en) | 2013-05-01 | 2018-01-02 | Isis Pharmaceuticals Inc | COMPOUNDS AND COMPOSITIONS FOR MODULING APOLIPOPROTEIN(A) EXPRESSION AND THEIR USES |
| TW201534578A (en)* | 2013-07-08 | 2015-09-16 | Daiichi Sankyo Co Ltd | Novel lipid |
| EP3052106A4 (en) | 2013-09-30 | 2017-07-19 | ModernaTX, Inc. | Polynucleotides encoding immune modulating polypeptides |
| BR112016007255A2 (en) | 2013-10-03 | 2017-09-12 | Moderna Therapeutics Inc | polynucleotides encoding low density lipoprotein receptor |
| CN106413811A (en) | 2013-10-22 | 2017-02-15 | 夏尔人类遗传性治疗公司 | Mrna therapy for argininosuccinate synthetase deficiency |
| KR102096796B1 (en) | 2013-10-22 | 2020-05-27 | 샤이어 휴먼 지네틱 테라피즈 인크. | Lipid formulations for delivery of messenger rna |
| EA201992208A1 (en) | 2013-10-22 | 2020-07-31 | Транслейт Био, Инк. | TREATMENT OF PHENYLKETONURIA USING mRNA |
| EP4036241A1 (en) | 2013-10-22 | 2022-08-03 | Translate Bio, Inc. | Cns delivery of mrna and uses thereof |
| KR101647178B1 (en)* | 2013-11-28 | 2016-08-23 | 충남대학교산학협력단 | Stabilized Plasmid-Lipid Particles Using polyethylen glycol-lipid composed of an Enzymatically Cleavable Linker or oligo-lysines |
| US10821175B2 (en) | 2014-02-25 | 2020-11-03 | Merck Sharp & Dohme Corp. | Lipid nanoparticle vaccine adjuvants and antigen delivery systems |
| LT3981437T (en) | 2014-04-23 | 2025-01-10 | Modernatx, Inc. | Nucleic acid vaccines |
| SG11201608725YA (en) | 2014-04-25 | 2016-11-29 | Shire Human Genetic Therapies | Methods for purification of messenger rna |
| EP3647318B1 (en) | 2014-04-28 | 2021-06-30 | Ionis Pharmaceuticals, Inc. | Linkage modified oligomeric compounds |
| ES2844593T3 (en) | 2014-05-01 | 2021-07-22 | Ionis Pharmaceuticals Inc | Compositions and procedures to modulate the expression of angiopoietin type 3 |
| KR102366078B1 (en) | 2014-05-01 | 2022-02-21 | 아이오니스 파마수티컬즈, 인코포레이티드 | Compositions and methods for modulating pkk expression |
| JP6667453B2 (en) | 2014-05-01 | 2020-03-18 | アイオーニス ファーマシューティカルズ， インコーポレーテッドＩｏｎｉｓ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． | Compositions and methods for modulating growth hormone receptor expression |
| KR102369736B1 (en) | 2014-05-01 | 2022-03-02 | 아이오니스 파마수티컬즈, 인코포레이티드 | Compositions and methods for modulating complement factor b expression |
| WO2015179693A1 (en) | 2014-05-22 | 2015-11-26 | Isis Pharmaceuticals, Inc. | Conjugated antisense compounds and their use |
| CN105085295A (en)* | 2014-05-23 | 2015-11-25 | 上海交通大学 | Amphiphilic derivative of tranexamic acid, and use thereof |
| CN105085292B (en)* | 2014-05-23 | 2017-12-15 | 上海交通大学 | Amphipathic derivatives of 3 ((2 (dimethylamino) ethyl group) (methyl) amino) propionic acid and application thereof |
| CN105085437B (en)* | 2014-05-23 | 2018-07-03 | 上海交通大学 | Amphipathic derivatives of 3- (1- tert-butoxy carbonyl piperazines -4-yl) propionic acid and application thereof |
| CA3211902A1 (en) | 2014-05-30 | 2015-12-03 | Translate Bio, Inc. | Biodegradable lipids for delivery of nucleic acids |
| PE20171238A1 (en) | 2014-06-24 | 2017-08-24 | Shire Human Genetic Therapies | STEREOCHEMICALLY ENRICHED COMPOSITIONS FOR NUCLEIC ACIDS ADMINISTRATION |
| IL289934B2 (en) | 2014-06-25 | 2023-04-01 | Acuitas Therapeutics Inc | Novel lipids and lipid nanoparticle formulations for delivery of nucleic acids |
| KR20170023004A (en) | 2014-06-30 | 2017-03-02 | 교와 핫꼬 기린 가부시키가이샤 | Cationic lipid |
| EP3164112A1 (en) | 2014-07-02 | 2017-05-10 | Shire Human Genetic Therapies, Inc. | Encapsulation of messenger rna |
| WO2016010840A1 (en) | 2014-07-16 | 2016-01-21 | Novartis Ag | Method of encapsulating a nucleic acid in a lipid nanoparticle host |
| WO2016021683A1 (en) | 2014-08-07 | 2016-02-11 | 武田薬品工業株式会社 | Cationic lipid |
| HRP20221055T1 (en) | 2014-08-29 | 2022-12-23 | Alnylam Pharmaceuticals, Inc. | Patisiran for use in treating transthyretin mediated amyloidosis |
| BR112017004056A2 (en) | 2014-09-12 | 2017-12-05 | Biogen Ma Inc | compositions and methods for detecting smn protein in an individual and treating an individual |
| JOP20200092A1 (en) | 2014-11-10 | 2017-06-16 | Alnylam Pharmaceuticals Inc | HEPATITIS B VIRUS (HBV) iRNA COMPOSITIONS AND METHODS OF USE THEREOF |
| WO2016081444A1 (en) | 2014-11-17 | 2016-05-26 | Alnylam Pharmaceuticals, Inc. | Apolipoprotein c3 (apoc3) irna compositions and methods of use thereof |
| EP3884964A1 (en) | 2014-12-05 | 2021-09-29 | Translate Bio, Inc. | Messenger rna therapy for treatment of articular disease |
| CA2979695A1 (en) | 2015-03-19 | 2016-09-22 | Translate Bio, Inc. | Mrna therapy for pompe disease |
| US11298326B2 (en) | 2015-03-24 | 2022-04-12 | Kyowa Kirin Co., Ltd. | Nucleic acid-containing lipid nanoparticles |
| CN104892473B (en)* | 2015-04-16 | 2017-01-11 | 武汉工程大学 | 4-mercapto-1-butanol synthesis process |
| EP3283125B1 (en) | 2015-04-17 | 2021-12-29 | CureVac Real Estate GmbH | Lyophilization of rna |
| SG10201910431RA (en) | 2015-05-20 | 2020-01-30 | Curevac Ag | Dry powder composition comprising long-chain rna |
| US10729654B2 (en) | 2015-05-20 | 2020-08-04 | Curevac Ag | Dry powder composition comprising long-chain RNA |
| WO2016209862A1 (en) | 2015-06-23 | 2016-12-29 | Alnylam Pharmaceuticals, Inc. | Glucokinase (gck) irna compositions and methods of use thereof |
| PL3313829T3 (en) | 2015-06-29 | 2024-08-19 | Acuitas Therapeutics Inc. | Lipids and lipid nanoparticle formulations for delivery of nucleic acids |
| KR102640776B1 (en) | 2015-07-10 | 2024-02-23 | 아이오니스 파마수티컬즈, 인코포레이티드 | Diacylglycerol acyltransferase 2 (DGAT2) regulator |
| JP2018150239A (en)* | 2015-07-15 | 2018-09-27 | 協和発酵キリン株式会社 | β2GPI GENE SILENCING RNAi PHARMACEUTICAL COMPOSITION |
| ES2937963T3 (en) | 2015-07-21 | 2023-04-03 | Modernatx Inc | Infectious disease vaccines |
| US11364292B2 (en) | 2015-07-21 | 2022-06-21 | Modernatx, Inc. | CHIKV RNA vaccines |
| JP2018521084A (en)* | 2015-07-24 | 2018-08-02 | フィブラリン コーポレイションＦｉｂｒａｌｉｇｎ Ｃｏｒｐ． | Compositions for targeted delivery of nucleic acid based therapeutics |
| DK3329002T3 (en) | 2015-07-31 | 2021-01-11 | Alnylam Pharmaceuticals Inc | TRANSTHYRETIN (TTR) IRNA COMPOSITIONS AND METHODS FOR USING IT FOR THE TREATMENT OR PREVENTION OF TTR-ASSOCIATED DISEASES |
| WO2017031232A1 (en)* | 2015-08-17 | 2017-02-23 | Modernatx, Inc. | Methods for preparing particles and related compositions |
| EP3336094A4 (en)* | 2015-08-25 | 2018-07-18 | Kyushu University | Novel sugar derivative gelling agent |
| JP7028764B2 (en) | 2015-09-02 | 2022-03-02 | アルナイラム ファーマシューティカルズ， インコーポレイテッド | Programmed cell death 1 Ligand 1 (PD-L1) iRNA composition and its usage |
| ES2908449T3 (en) | 2015-09-17 | 2022-04-29 | Modernatx Inc | Polynucleotides that contain a stabilizing tail region |
| LT3350157T (en) | 2015-09-17 | 2022-02-25 | Modernatx, Inc. | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC SUBSTANCES |
| EP3353328A4 (en) | 2015-09-24 | 2019-06-12 | Ionis Pharmaceuticals, Inc. | MODULATORS OF KRAS EXPRESSION |
| CN108472358B (en)* | 2015-09-30 | 2022-06-24 | 盐野义制药株式会社 | Nucleic acid derivatives with immunopotentiating activity |
| US10940201B2 (en)* | 2015-09-30 | 2021-03-09 | Shionogi & Co., Ltd. | Nucleic acid derivative having immunostimulatory activity |
| EP3359670B2 (en) | 2015-10-05 | 2024-02-14 | ModernaTX, Inc. | Methods for therapeutic administration of messenger ribonucleic acid drugs |
| MA56219A (en) | 2015-10-14 | 2022-04-20 | Translate Bio Inc | MODIFICATION OF RNA-RELATED ENZYMES FOR ENHANCED PRODUCTION |
| WO2017070613A1 (en) | 2015-10-22 | 2017-04-27 | Modernatx, Inc. | Human cytomegalovirus vaccine |
| JP6925688B2 (en) | 2015-10-22 | 2021-08-25 | モデルナティーエックス， インコーポレイテッド | Nucleic acid vaccine for varicella-zoster virus (VZV) |
| JP2018531290A (en) | 2015-10-22 | 2018-10-25 | モデルナティーエックス， インコーポレイテッド | Sexually transmitted disease vaccine |
| EP3364950A4 (en) | 2015-10-22 | 2019-10-23 | ModernaTX, Inc. | VACCINES AGAINST TROPICAL DISEASES |
| EP4349405A3 (en) | 2015-10-22 | 2024-06-19 | ModernaTX, Inc. | Respiratory virus vaccines |
| BR112018008102A2 (en)* | 2015-10-22 | 2018-11-06 | Modernatx Inc | respiratory syncytial virus vaccine |
| WO2018081480A1 (en) | 2016-10-26 | 2018-05-03 | Acuitas Therapeutics, Inc. | Lipid nanoparticle formulations |
| HUE061564T2 (en) | 2015-10-28 | 2023-07-28 | Acuitas Therapeutics Inc | New lipids and lipid nanoparticle formulations for nucleic acid delivery |
| HUE068702T2 (en) | 2015-11-06 | 2025-01-28 | Ionis Pharmaceuticals Inc | Conjugated antisense compounds for use in therapy |
| NZ740026A (en) | 2015-11-06 | 2025-07-25 | Ionis Pharmaceuticals Inc | Modulating apolipoprotein (a) expression |
| CA3007955A1 (en) | 2015-12-10 | 2017-06-15 | Modernatx, Inc. | Lipid nanoparticles for delivery of therapeutic agents |
| HRP20220268T1 (en) | 2015-12-22 | 2022-05-13 | Modernatx, Inc. | Compounds and compositions for intracellular delivery of agents |
| CA3009131C (en) | 2015-12-25 | 2024-06-04 | Kyowa Hakko Kirin Co., Ltd. | Compounds as cationic lipids and their use in nucleic acid delivery compositions |
| CA3011946A1 (en) | 2016-03-07 | 2017-09-14 | Arrowhead Pharmaceuticals, Inc. | Targeting ligands for therapeutic compounds |
| EP3436066A1 (en) | 2016-04-01 | 2019-02-06 | Checkmate Pharmaceuticals, Inc. | Fc receptor-mediated drug delivery |
| AU2017248189B2 (en) | 2016-04-08 | 2021-04-29 | Translate Bio, Inc. | Multimeric coding nucleic acid and uses thereof |
| EP3448393A1 (en) | 2016-04-25 | 2019-03-06 | Invivogen | Novel complexes of immunostimulatory compounds, and uses thereof |
| EP3458107B1 (en) | 2016-05-18 | 2024-03-13 | ModernaTX, Inc. | Polynucleotides encoding jagged1 for the treatment of alagille syndrome |
| CN115837014A (en) | 2016-05-18 | 2023-03-24 | 摩登纳特斯有限公司 | Polynucleotide encoding relaxin |
| CN106046118A (en)* | 2016-05-26 | 2016-10-26 | 首都医科大学 | Preparation of siRNA transfer system comprising S-Beta-carboline-3-acyl-RGDV and application of system in SURVIVIN gene silencing |
| WO2017218524A1 (en) | 2016-06-13 | 2017-12-21 | Rana Therapeutics, Inc. | Messenger rna therapy for the treatment of ornithine transcarbamylase deficiency |
| US10927383B2 (en) | 2016-06-30 | 2021-02-23 | Ethris Gmbh | Cas9 mRNAs |
| SG11201900238UA (en) | 2016-07-15 | 2019-02-27 | Ionis Pharmaceuticals Inc | Compounds and methods for modulation of smn2 |
| US20190185859A1 (en) | 2016-08-19 | 2019-06-20 | Curevac Ag | Rna for cancer therapy |
| SG10201912835QA (en) | 2016-09-02 | 2020-02-27 | Arrowhead Pharmaceuticals Inc | Targeting ligands |
| AU2017326253B2 (en) | 2016-09-13 | 2021-10-21 | Allergan, Inc. | Stabilized non-protein clostridial toxin compositions |
| US11471533B2 (en) | 2016-09-27 | 2022-10-18 | Kyowa Kirin Co., Ltd. | Compound usable as cationic lipid |
| TW201813632A (en)* | 2016-09-28 | 2018-04-16 | 日商協和醱酵麒麟有限公司 | Nucleic-acid-containing lipid nanoparticles |
| KR20190065341A (en) | 2016-10-06 | 2019-06-11 | 아이오니스 파마수티컬즈, 인코포레이티드 | Method of joining oligomeric compounds |
| EP3527570A4 (en) | 2016-10-14 | 2020-04-15 | Jiangsu Hengrui Medicine Co., Ltd. | Five-membered heteroaryl ring bridged ring derivative, preparation method therefor and medical use thereof |
| MA46584A (en) | 2016-10-21 | 2019-08-28 | Modernatx Inc | HUMAN CYTOMEGALOVIRUS VACCINE |
| US11583504B2 (en) | 2016-11-08 | 2023-02-21 | Modernatx, Inc. | Stabilized formulations of lipid nanoparticles |
| WO2018087753A1 (en)* | 2016-11-08 | 2018-05-17 | Technology Innovation Momentum Fund (Israel) Limited Partnership | Cationic lipids for nucleic acid delivery and preparation thereof |
| MA46766A (en) | 2016-11-11 | 2019-09-18 | Modernatx Inc | INFLUENZA VACCINE |
| EP3551193A4 (en) | 2016-12-08 | 2020-08-19 | Modernatx, Inc. | NUCLEIC ACID VACCINES AGAINST RESPIRATORY VIRUS |
| US11542490B2 (en) | 2016-12-08 | 2023-01-03 | CureVac SE | RNAs for wound healing |
| US11464836B2 (en) | 2016-12-08 | 2022-10-11 | Curevac Ag | RNA for treatment or prophylaxis of a liver disease |
| KR20240027888A (en) | 2016-12-14 | 2024-03-04 | 리간달 인코포레이티드 | Methods and compositions for nucleic acid and protein payload delivery |
| EP3558356A2 (en) | 2016-12-23 | 2019-10-30 | CureVac AG | Mers coronavirus vaccine |
| WO2018115507A2 (en) | 2016-12-23 | 2018-06-28 | Curevac Ag | Henipavirus vaccine |
| EP3558354A1 (en) | 2016-12-23 | 2019-10-30 | CureVac AG | Lassa virus vaccine |
| WO2018151816A1 (en) | 2017-02-16 | 2018-08-23 | Modernatx, Inc. | High potency immunogenic compositions |
| WO2018157154A2 (en) | 2017-02-27 | 2018-08-30 | Translate Bio, Inc. | Novel codon-optimized cftr mrna |
| WO2018170322A1 (en) | 2017-03-15 | 2018-09-20 | Modernatx, Inc. | Crystal forms of amino lipids |
| WO2018170256A1 (en) | 2017-03-15 | 2018-09-20 | Modernatx, Inc. | Herpes simplex virus vaccine |
| WO2018170245A1 (en) | 2017-03-15 | 2018-09-20 | Modernatx, Inc. | Broad spectrum influenza virus vaccine |
| WO2018170270A1 (en) | 2017-03-15 | 2018-09-20 | Modernatx, Inc. | Varicella zoster virus (vzv) vaccine |
| CA3055653A1 (en) | 2017-03-15 | 2018-09-20 | Modernatx, Inc. | Lipid nanoparticle formulation |
| JP7167049B2 (en) | 2017-03-15 | 2022-11-08 | モデルナティエックス インコーポレイテッド | Compounds and compositions for intracellular delivery of therapeutic agents |
| US11464848B2 (en) | 2017-03-15 | 2022-10-11 | Modernatx, Inc. | Respiratory syncytial virus vaccine |
| CA3050614A1 (en) | 2017-03-17 | 2018-09-20 | Curevac Ag | Rna vaccine and immune checkpoint inhibitors for combined anticancer therapy |
| EP3595676A4 (en) | 2017-03-17 | 2021-05-05 | Modernatx, Inc. | Zoonotic disease rna vaccines |
| WO2019012336A2 (en) | 2017-03-17 | 2019-01-17 | Newcastle University | Adeno-associated virus vector delivery of a fragment of micro-dystrophin to treat muscular dystrophy |
| US11739335B2 (en) | 2017-03-24 | 2023-08-29 | CureVac SE | Nucleic acids encoding CRISPR-associated proteins and uses thereof |
| JOP20190215A1 (en) | 2017-03-24 | 2019-09-19 | Ionis Pharmaceuticals Inc | Modulators of pcsk9 expression |
| US11433026B2 (en)* | 2017-03-31 | 2022-09-06 | University Of Rhode Island Board Of Trustees | Nanoparticle-induced fusogenicity between liposome and endosome membranes for targeted delivery through endosomal escape |
| US11905525B2 (en) | 2017-04-05 | 2024-02-20 | Modernatx, Inc. | Reduction of elimination of immune responses to non-intravenous, e.g., subcutaneously administered therapeutic proteins |
| US11357856B2 (en) | 2017-04-13 | 2022-06-14 | Acuitas Therapeutics, Inc. | Lipids for delivery of active agents |
| WO2018191719A1 (en) | 2017-04-13 | 2018-10-18 | Acuitas Therapeutics, Inc. | Lipid delivery of therapeutic agents to adipose tissue |
| TWI801377B (en) | 2017-04-18 | 2023-05-11 | 美商阿尼拉製藥公司 | Methods for the treatment of subjects having a hepatitis b virus (hbv) infection |
| AU2018256877B2 (en) | 2017-04-28 | 2022-06-02 | Acuitas Therapeutics, Inc. | Novel carbonyl lipids and lipid nanoparticle formulations for delivery of nucleic acids |
| US11173190B2 (en) | 2017-05-16 | 2021-11-16 | Translate Bio, Inc. | Treatment of cystic fibrosis by delivery of codon-optimized mRNA encoding CFTR |
| US11377643B2 (en) | 2017-05-31 | 2022-07-05 | Ultragenyx Pharmaceutical Inc. | Therapeutics for glycogen storage disease type III |
| WO2018222925A1 (en) | 2017-05-31 | 2018-12-06 | Ultragenyx Pharmaceutical Inc. | Therapeutics for phenylketonuria |
| US11015204B2 (en) | 2017-05-31 | 2021-05-25 | Arcturus Therapeutics, Inc. | Synthesis and structure of high potency RNA therapeutics |
| EP3638678A1 (en) | 2017-06-14 | 2020-04-22 | Modernatx, Inc. | Compounds and compositions for intracellular delivery of agents |
| US11786607B2 (en) | 2017-06-15 | 2023-10-17 | Modernatx, Inc. | RNA formulations |
| EP4494652A3 (en) | 2017-07-04 | 2025-05-14 | CureVac SE | Cancer rna-vaccine |
| US20210228738A1 (en) | 2017-07-17 | 2021-07-29 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Compositions and methods for increasing or enhancing transduction of gene therapy vectors and for removing or reducing immunoglobulins |
| US11633365B2 (en) | 2017-08-04 | 2023-04-25 | Kyowa Kirin Co., Ltd. | Nucleic acid-containing lipid nanoparticle |
| JP7355731B2 (en) | 2017-08-16 | 2023-10-03 | アクイタス セラピューティクス インコーポレイテッド | Lipids for use in lipid nanoparticle formulations |
| ES2997124T3 (en) | 2017-08-17 | 2025-02-14 | Acuitas Therapeutics Inc | Lipids for use in lipid nanoparticle formulations |
| US11542225B2 (en) | 2017-08-17 | 2023-01-03 | Acuitas Therapeutics, Inc. | Lipids for use in lipid nanoparticle formulations |
| US11524932B2 (en) | 2017-08-17 | 2022-12-13 | Acuitas Therapeutics, Inc. | Lipids for use in lipid nanoparticle formulations |
| WO2019038332A1 (en) | 2017-08-22 | 2019-02-28 | Curevac Ag | Bunyavirales vaccine |
| US11744801B2 (en) | 2017-08-31 | 2023-09-05 | Modernatx, Inc. | Methods of making lipid nanoparticles |
| MA50253A (en) | 2017-09-14 | 2020-07-22 | Modernatx Inc | ZIKA VIRUS RNA VACCINES |
| AU2018336806B2 (en) | 2017-09-19 | 2025-04-10 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for treating transthyretin (TTR) mediated amyloidosis |
| RU2020115287A (en) | 2017-10-19 | 2021-11-19 | Куревак Аг | NEW MOLECULES OF ARTIFICIAL NUCLEIC ACIDS |
| WO2019089828A1 (en) | 2017-10-31 | 2019-05-09 | Acuitas Therapeutics, Inc. | Lamellar lipid nanoparticles |
| SG11202003247RA (en) | 2017-11-08 | 2020-05-28 | Curevac Ag | Rna sequence adaptation |
| EP3714054A1 (en) | 2017-11-20 | 2020-09-30 | Alnylam Pharmaceuticals, Inc. | Serum amyloid p component (apcs) irna compositions and methods of use thereof |
| WO2019115635A1 (en) | 2017-12-13 | 2019-06-20 | Curevac Ag | Flavivirus vaccine |
| WO2019126593A1 (en) | 2017-12-20 | 2019-06-27 | Translate Bio, Inc. | Improved composition and methods for treatment of ornithine transcarbamylase deficiency |
| WO2019126144A1 (en) | 2017-12-22 | 2019-06-27 | North Carolina State University | Polymeric fluorophores, compositions comprising the same, and methods of preparing and using the same |
| IL275567B2 (en) | 2017-12-27 | 2024-03-01 | Takeda Pharmaceuticals Co | Nucleic acid-containing lipid nano-particle and use thereof |
| EP3740575A1 (en) | 2018-01-15 | 2020-11-25 | Ionis Pharmaceuticals, Inc. | Modulators of dnm2 expression |
| US11911453B2 (en) | 2018-01-29 | 2024-02-27 | Modernatx, Inc. | RSV RNA vaccines |
| US11332733B2 (en) | 2018-02-12 | 2022-05-17 | lonis Pharmaceuticals, Inc. | Modified compounds and uses thereof |
| WO2019160866A2 (en) | 2018-02-13 | 2019-08-22 | Checkmate Pharmaceuticals, Inc. | Compositions and methods for tumor immunotherapy |
| CN108310455B (en)* | 2018-03-20 | 2021-07-30 | 嘉兴尔云信息科技有限公司 | Nano hydroxyapatite and PGS-M composite bone repair material and preparation method thereof |
| US20210361761A1 (en) | 2018-04-05 | 2021-11-25 | Curevac Ag | Novel yellow fever nucleic acid molecules for vaccination |
| KR20210006905A (en) | 2018-04-09 | 2021-01-19 | 체크메이트 파마슈티칼스 | Packaging of oligonucleotides into virus-like particles |
| CN112292395A (en) | 2018-04-17 | 2021-01-29 | 库瑞瓦格股份公司 | Novel RSV RNA molecules and compositions for vaccination |
| CA3098136A1 (en) | 2018-05-09 | 2019-11-14 | Ionis Pharmaceuticals, Inc. | Compounds and methods for reducing fxi expression |
| CN112262122B (en) | 2018-06-08 | 2023-10-13 | 富士胶片株式会社 | Compounds or salts thereof and lipid particles |
| US20210260178A1 (en) | 2018-06-27 | 2021-08-26 | Curevac Ag | Novel lassa virus rna molecules and compositions for vaccination |
| EP3833397A4 (en) | 2018-08-08 | 2023-06-14 | Arcturus Therapeutics, Inc. | COMPOSITIONS AND AGENTS AGAINST NON-ALCOHOLIC STEATOHEPATITIS |
| US20210317461A1 (en) | 2018-08-09 | 2021-10-14 | Verseau Therapeutics, Inc. | Oligonucleotide compositions for targeting ccr2 and csf1r and uses thereof |
| EP3841208A1 (en) | 2018-08-24 | 2021-06-30 | Translate Bio, Inc. | Methods for purification of messenger rna |
| CA3113025A1 (en) | 2018-09-19 | 2020-03-26 | Modernatx, Inc. | Peg lipids and uses thereof |
| AU2019345067A1 (en) | 2018-09-19 | 2021-04-08 | Modernatx, Inc. | High-purity peg lipids and uses thereof |
| TWI869213B (en) | 2018-09-19 | 2025-01-01 | 美商Ionis製藥公司 | Modulators of pnpla3 expression |
| CA3113436A1 (en) | 2018-09-19 | 2020-03-26 | Modernatx, Inc. | Compounds and compositions for intracellular delivery of therapeutic agents |
| EP3852728B1 (en) | 2018-09-20 | 2024-09-18 | ModernaTX, Inc. | Preparation of lipid nanoparticles and methods of administration thereof |
| EP3852911B1 (en) | 2018-09-21 | 2025-01-22 | Acuitas Therapeutics, Inc. | Systems and methods for manufacturing lipid nanoparticles and liposomes |
| CA3111476A1 (en) | 2018-09-28 | 2020-04-02 | Nutcracker Therapeutics, Inc. | Lipid nanoparticle formulations comprising lipidated cationic peptide compounds for nucleic acid delivery |
| EP3860561B1 (en) | 2018-10-01 | 2023-06-21 | Alnylam Pharmaceuticals, Inc. | Biodegradable lipids for the delivery of active agents |
| KR20210093232A (en) | 2018-10-09 | 2021-07-27 | 더 유니버시티 오브 브리티시 콜롬비아 | Compositions and systems and related methods comprising transfection competent vesicles free of organic solvent and detergent |
| CN119876276A (en) | 2018-10-18 | 2025-04-25 | 武田药品工业株式会社 | T cell activation/proliferation method |
| JP7543259B2 (en)* | 2018-10-18 | 2024-09-02 | アクイタス セラピューティクス インコーポレイテッド | Lipids for lipid nanoparticle delivery of active agents |
| ES2971849T3 (en)* | 2018-11-21 | 2024-06-10 | Translate Bio Inc | Cationic lipid compounds and compositions thereof for use in the delivery of messenger RNA |
| WO2020106946A1 (en) | 2018-11-21 | 2020-05-28 | Translate Bio, Inc. | TREATMENT OF CYSTIC FIBROSIS BY DELIVERY OF NEBULIZED mRNA ENCODING CFTR |
| WO2020118115A1 (en) | 2018-12-06 | 2020-06-11 | Arcturus Therapeutics, Inc. | Compositions and methods for treating ornithine transcarbamylase deficiency |
| TW202039534A (en) | 2018-12-14 | 2020-11-01 | 美商美國禮來大藥廠 | Kras variant mrna molecules |
| EP3897702A2 (en) | 2018-12-21 | 2021-10-27 | CureVac AG | Rna for malaria vaccines |
| JOP20210158A1 (en) | 2018-12-21 | 2023-01-30 | Ionis Pharmaceuticals Inc | Modulators of hsd17b13 expression |
| HUE068416T2 (en) | 2019-01-11 | 2024-12-28 | Acuitas Therapeutics Inc | Lipids for lipid nanoparticle delivery of active agents |
| WO2020161342A1 (en) | 2019-02-08 | 2020-08-13 | Curevac Ag | Coding rna administered into the suprachoroidal space in the treatment of ophtalmic diseases |
| US11351242B1 (en) | 2019-02-12 | 2022-06-07 | Modernatx, Inc. | HMPV/hPIV3 mRNA vaccine composition |
| US12070495B2 (en) | 2019-03-15 | 2024-08-27 | Modernatx, Inc. | HIV RNA vaccines |
| CN112010995A (en)* | 2019-05-30 | 2020-12-01 | 株式会社大赛璐 | Chitosan derivative and separating agent for optical isomer |
| CN110041223B (en)* | 2019-06-03 | 2021-10-22 | 西北师范大学 | Method for oxidative synthesis of azo compounds using hydrazine compounds as raw materials |
| JP7241869B2 (en) | 2019-06-07 | 2023-03-17 | 富士フイルム株式会社 | Lipid composition |
| EP3986452A1 (en) | 2019-06-18 | 2022-04-27 | CureVac AG | Rotavirus mrna vaccine |
| JP7416096B2 (en)* | 2019-06-20 | 2024-01-17 | プレシジョン ナノシステムズ ユーエルシー | Ionizable lipids for nucleic acid delivery |
| EP3990441A4 (en)* | 2019-06-29 | 2022-08-24 | Precision Nanosystems Inc | IONIZABLE LIPIDS FOR NUCLEIC ACID DELIVERY |
| WO2021016075A1 (en) | 2019-07-19 | 2021-01-28 | Flagship Pioneering Innovations Vi, Llc | Recombinase compositions and methods of use |
| WO2021030522A1 (en) | 2019-08-13 | 2021-02-18 | Alnylam Pharmaceuticals, Inc. | SMALL RIBOSOMAL PROTEIN SUBUNIT 25 (RPS25) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF |
| WO2021030701A1 (en) | 2019-08-14 | 2021-02-18 | Acuitas Therapeutics, Inc. | Improved lipid nanoparticles for delivery of nucleic acids |
| JP2022544412A (en) | 2019-08-14 | 2022-10-18 | キュアバック アーゲー | RNA combinations and compositions with reduced immunostimulatory properties |
| WO2021055833A1 (en) | 2019-09-19 | 2021-03-25 | Modernatx, Inc. | Branched tail lipid compounds and compositions for intracellular delivery of therapeutic agents |
| JP2022552249A (en) | 2019-10-14 | 2022-12-15 | アストラゼネカ・アクチエボラーグ | Modulators of PNPLA3 expression |
| JP2023500661A (en) | 2019-11-01 | 2023-01-10 | アルナイラム ファーマシューティカルズ， インコーポレイテッド | HUNTINGTIN (HTT) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF |
| KR20240090627A (en) | 2019-11-15 | 2024-06-21 | 후지필름 가부시키가이샤 | Lipid composition |
| WO2021102373A1 (en) | 2019-11-22 | 2021-05-27 | Alnylam Pharmaceuticals, Inc. | Ataxin3 (atxn3) rnai agent compositions and methods of use thereof |
| MX2022006433A (en) | 2019-12-13 | 2022-06-23 | Alnylam Pharmaceuticals Inc | Human chromosome 9 open reading frame 72 (c9orf72) irna agent compositions and methods of use thereof. |
| CN114901360A (en) | 2019-12-20 | 2022-08-12 | 库瑞瓦格股份公司 | Novel lipid nanoparticles for delivery of nucleic acids |
| KR20220144416A (en) | 2020-02-04 | 2022-10-26 | 큐어백 아게 | coronavirus vaccine |
| TW202517787A (en) | 2020-02-28 | 2025-05-01 | 美商Ionis製藥公司 | Compounds and methods for modulating smn2 |
| JP2023516676A (en) | 2020-03-03 | 2023-04-20 | アークトゥラス・セラピューティクス・インコーポレイテッド | Compositions and methods for the treatment of ornithine transcarbamylase deficiency |
| WO2021178607A1 (en) | 2020-03-05 | 2021-09-10 | Alnylam Pharmaceuticals, Inc. | Complement component c3 irna compositions and methods of use thereof for treating or preventing complement component c3-associated diseases |
| EP4117720A4 (en) | 2020-03-09 | 2024-04-24 | Arcturus Therapeutics, Inc. | COMPOSITIONS AND METHODS FOR INDUCING IMMUNE RESPONSES |
| EP4121018A4 (en)* | 2020-03-17 | 2024-07-03 | Genevant Sciences Gmbh | CATIONIC LIPIDS FOR THE DELIVERY OF LIPID NANOPARTICLES OF THERAPEUTIC AGENTS TO HEPATIC STELLAR CELLS |
| EP4127186A1 (en) | 2020-03-24 | 2023-02-08 | Generation Bio Co. | Non-viral dna vectors and uses thereof for expressing gaucher therapeutics |
| KR20230003477A (en) | 2020-03-24 | 2023-01-06 | 제너레이션 바이오 컴퍼니 | Non-viral DNA vectors and their use for expressing Factor IX therapeutics |
| EP4127168A1 (en) | 2020-03-26 | 2023-02-08 | Alnylam Pharmaceuticals, Inc. | Coronavirus irna compositions and methods of use thereof |
| US20240043527A1 (en) | 2020-03-30 | 2024-02-08 | BioNTech SE | Rna compositions targeting claudin-18.2 |
| EP4133076A1 (en) | 2020-04-07 | 2023-02-15 | Alnylam Pharmaceuticals, Inc. | Angiotensin-converting enzyme 2 (ace2) irna compositions and methods of use thereof |
| WO2021206922A1 (en) | 2020-04-07 | 2021-10-14 | Alnylam Pharmaceuticals, Inc. | Transmembrane serine protease 2 (tmprss2) irna compositions and methods of use thereof |
| KR20230012508A (en) | 2020-04-21 | 2023-01-26 | 플래그쉽 파이어니어링, 인크. | Bifunctional Molecules and Methods of Their Use |
| BR112022021813A2 (en) | 2020-04-27 | 2023-01-17 | Alnylam Pharmaceuticals Inc | APOLIPOPROTEIN AND (APOE) IRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF |
| EP4143217A4 (en) | 2020-05-01 | 2024-10-02 | Arcturus Therapeutics, Inc. | NUCLEIC ACIDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS |
| CN111575310B (en)* | 2020-05-14 | 2022-12-13 | 江南大学 | Recombinant saccharomyces cerevisiae expressing caveolin and its application |
| AU2021275213A1 (en) | 2020-05-20 | 2023-02-02 | Flagship Pioneering Innovations Vi, Llc | Immunogenic compositions and uses thereof |
| CN116322760A (en) | 2020-05-20 | 2023-06-23 | 旗舰创业创新第六有限责任公司 | Coronavirus antigen composition and use thereof |
| AU2021281453A1 (en) | 2020-05-29 | 2022-11-17 | Flagship Pioneering Innovations Vi, Llc. | Trem compositions and methods relating thereto |
| MX2022015132A (en) | 2020-05-29 | 2023-03-08 | CureVac SE | Nucleic acid based combination vaccines. |
| IL298539A (en) | 2020-05-29 | 2023-01-01 | Flagship Pioneering Innovations Vi Llc | trem compositions and methods related thereto |
| WO2021252557A1 (en) | 2020-06-09 | 2021-12-16 | Alnylam Pharmaceuticals, Inc. | Rnai compositions and methods of use thereof for delivery by inhalation |
| BR112022025586A2 (en) | 2020-06-15 | 2023-03-07 | Res Inst Nationwide Childrens Hospital | ADENO-ASSOCIATED VIRUS VECTOR RELEASE FOR MUSCULAR DYSTROPHIES |
| EP4165012A1 (en)* | 2020-06-16 | 2023-04-19 | Rhodia Operations | New ammonium compounds useful as surfactants |
| CN111714468B (en)* | 2020-06-30 | 2022-02-11 | 郑州大学 | A kind of siRNA delivery system complex and its preparation method and use |
| PH12023550030A1 (en) | 2020-07-08 | 2024-03-11 | Janssen Sciences Ireland Unlimited Co | Rna replicon vaccines against hbv |
| CN116096702A (en) | 2020-07-16 | 2023-05-09 | 爱康泰生治疗公司 | Cationic Lipids for Lipid Nanoparticles |
| AU2021314809A1 (en) | 2020-07-27 | 2023-02-23 | Anjarium Biosciences Ag | Compositions of DNA molecules, methods of making therefor, and methods of use thereof |
| WO2022023559A1 (en) | 2020-07-31 | 2022-02-03 | Curevac Ag | Nucleic acid encoded antibody mixtures |
| AU2021325945A1 (en) | 2020-08-14 | 2023-04-06 | Arcturus Therapeutics, Inc. | Method of lyophilizing lipid nanoparticles |
| US11406703B2 (en) | 2020-08-25 | 2022-08-09 | Modernatx, Inc. | Human cytomegalovirus vaccine |
| EP4157344A2 (en) | 2020-08-31 | 2023-04-05 | CureVac SE | Multivalent nucleic acid based coronavirus vaccines |
| EP4208196A1 (en) | 2020-09-03 | 2023-07-12 | Flagship Pioneering Innovations VI, LLC | Immunogenic compositions and uses thereof |
| WO2022054955A1 (en) | 2020-09-14 | 2022-03-17 | 富士フイルム株式会社 | Lipid composition |
| EP4213882A4 (en) | 2020-09-15 | 2025-02-26 | Verve Therapeutics, Inc. | TAL EFFECTOR NUCLEASES FOR GENE EDITING |
| US20230331670A1 (en)* | 2020-09-17 | 2023-10-19 | Enzychem Lifesciences Corporation | Glycerol compounds and methods of use |
| EP4217489A1 (en) | 2020-09-24 | 2023-08-02 | Alnylam Pharmaceuticals, Inc. | Dipeptidyl peptidase 4 (dpp4) irna compositions and methods of use thereof |
| TW202229552A (en) | 2020-10-05 | 2022-08-01 | 美商艾拉倫製藥股份有限公司 | G protein-coupled receptor 75 (gpr75) irna compositions and methods of use thereof |
| KR20230113285A (en)* | 2020-10-09 | 2023-07-28 | 아다르엑스 파마슈티컬스, 인크. | N-acetylgalactosamine (GAlNAc)-derived compounds and oligonucleotides |
| IL301890A (en)* | 2020-10-14 | 2023-06-01 | George Mason Res Foundation Inc | Ionizing fats and methods of production and use thereof |
| WO2022087329A1 (en) | 2020-10-23 | 2022-04-28 | Alnylam Pharmaceuticals, Inc. | Mucin 5b (muc5b) irna compositions and methods of use thereof |
| CA3201661A1 (en) | 2020-11-18 | 2022-05-27 | Ionis Pharmaceuticals, Inc. | Compounds and methods for modulating angiotensinogen expression |
| CA3200234A1 (en) | 2020-11-25 | 2022-06-02 | Daryl C. Drummond | Lipid nanoparticles for delivery of nucleic acids, and related methods of use |
| CA3171051A1 (en) | 2020-12-22 | 2022-06-30 | Curevac Ag | Pharmaceutical composition comprising lipid-based carriers encapsulating rna for multidose administration |
| IL303855A (en)* | 2020-12-22 | 2023-08-01 | Univ Cornell | Zwitterionic lipid nanoparticle compositions and methods of use |
| WO2022137133A1 (en) | 2020-12-22 | 2022-06-30 | Curevac Ag | Rna vaccine against sars-cov-2 variants |
| US20240175020A1 (en) | 2020-12-23 | 2024-05-30 | Flagship Pioneering Innovations Vi, Llc | Compositions of modified trems and uses thereof |
| US20240316090A1 (en) | 2020-12-28 | 2024-09-26 | Arcturus Therapeutics, Inc. | Transcription activator-like effector nucleases (talens) targeting hbv |
| WO2022155404A1 (en)* | 2021-01-14 | 2022-07-21 | Translate Bio, Inc. | Methods and compositions for delivering mrna coded antibodies |
| US20240102065A1 (en) | 2021-01-27 | 2024-03-28 | CureVac SE | Method of reducing the immunostimulatory properties of in vitro transcribed rna |
| TW202245835A (en) | 2021-02-04 | 2022-12-01 | 美商默沙東有限責任公司 | Nanoemulsion adjuvant composition for pneumococcal conjugate vaccines |
| WO2022168884A1 (en) | 2021-02-04 | 2022-08-11 | 塩野義製薬株式会社 | Cationic lipid |
| CA3210763A1 (en) | 2021-02-12 | 2022-08-18 | Alnylam Pharmaceuticals, Inc. | Superoxide dismutase 1 (sod1) irna compositions and methods of use thereof for treating or preventing superoxide dismutase 1- (sod1-) associated neurodegenerative diseases |
| US11524023B2 (en) | 2021-02-19 | 2022-12-13 | Modernatx, Inc. | Lipid nanoparticle compositions and methods of formulating the same |
| EP4298220A1 (en) | 2021-02-25 | 2024-01-03 | Alnylam Pharmaceuticals, Inc. | Prion protein (prnp) irna compositions and methods of use thereof |
| EP4305169A1 (en) | 2021-03-12 | 2024-01-17 | Alnylam Pharmaceuticals, Inc. | Glycogen synthase kinase 3 alpha (gsk3a) irna compositions and methods of use thereof |
| MX2023011400A (en) | 2021-03-26 | 2023-10-09 | Glaxosmithkline Biologicals Sa | Immunogenic compositions. |
| MX2023011466A (en) | 2021-03-29 | 2024-02-01 | Alnylam Pharmaceuticals Inc | Huntingtin (htt) irna agent compositions and methods of use thereof. |
| EP4313109A1 (en) | 2021-03-31 | 2024-02-07 | Flagship Pioneering Innovations V, Inc. | Thanotransmission polypeptides and their use in treating cancer |
| WO2022207862A2 (en) | 2021-03-31 | 2022-10-06 | Curevac Ag | Syringes containing pharmaceutical compositions comprising rna |
| EP4319803A1 (en) | 2021-04-08 | 2024-02-14 | Vaxthera SAS | Coronavirus vaccine comprising a mosaic protein |
| US20240148664A1 (en)* | 2021-04-09 | 2024-05-09 | Sogo Pharmaceutical Co., Ltd. | Lipid and composition |
| CA3214538A1 (en) | 2021-04-20 | 2022-10-27 | Joel DE BEER | Compositions of dna molecules encoding amylo-alpha-1, 6-glucosidase, 4-alpha-glucanotransferase, methods of making thereof, and methods of use thereof |
| US20240216535A1 (en) | 2021-04-27 | 2024-07-04 | Generation Bio Co. | Non-viral dna vectors expressing anti-coronavirus antibodies and uses thereof |
| AU2022264509A1 (en) | 2021-04-27 | 2023-12-14 | Generation Bio Co. | Non-viral dna vectors expressing therapeutic antibodies and uses thereof |
| CA3216416A1 (en) | 2021-04-28 | 2022-11-03 | Shintaro TANABE | Compound or salt thereof, lipid particles, and pharmaceutical composition |
| WO2022232343A1 (en) | 2021-04-29 | 2022-11-03 | Alnylam Pharmaceuticals, Inc. | Signal transducer and activator of transcription factor 6 (stat6) irna compositions and methods of use thereof |
| WO2022233880A1 (en) | 2021-05-03 | 2022-11-10 | Curevac Ag | Improved nucleic acid sequence for cell type specific expression |
| EP4341401A1 (en) | 2021-05-18 | 2024-03-27 | Alnylam Pharmaceuticals, Inc. | Sodium-glucose cotransporter-2 (sglt2) irna compositions and methods of use thereof |
| EP4342993A4 (en)* | 2021-05-19 | 2025-05-28 | Daiichi Sankyo Company, Limited | VACCINE AGAINST INFECTIOUS DISEASES CAUSED BY HPV |
| AU2022282812A1 (en)* | 2021-05-28 | 2023-11-09 | Nanovation Therapeutics Inc. | Mc3-type lipids and use thereof in the preparation of lipid nanoparticles |
| WO2022246555A1 (en)* | 2021-05-28 | 2022-12-01 | Nanovation Therapeutics Inc. | Method for producing an ionizable lipid |
| CA3221245A1 (en) | 2021-06-04 | 2022-12-08 | Alnylam Pharmaceuticals, Inc. | Human chromosome 9 open reading frame 72 (c9orf72) irna agent compositions and methods of use thereof |
| KR20220167770A (en) | 2021-06-11 | 2022-12-21 | 주식회사 나이벡 | Nanoparticle Comprising Peptide-Lipid Conjugate for Delivering Oligonucleotide into Target Cell and Pharmaceutical Composition Comprising Thereof |
| WO2023009547A1 (en) | 2021-07-26 | 2023-02-02 | Flagship Pioneering Innovations Vi, Llc | Trem compositions and uses thereof |
| WO2023006999A2 (en) | 2021-07-30 | 2023-02-02 | CureVac SE | Mrnas for treatment or prophylaxis of liver diseases |
| CN117795074A (en) | 2021-08-03 | 2024-03-29 | 阿尔尼拉姆医药品有限公司 | Transthyretin (TTR) iRNA compositions and methods of use |
| WO2023023055A1 (en) | 2021-08-16 | 2023-02-23 | Renagade Therapeutics Management Inc. | Compositions and methods for optimizing tropism of delivery systems for rna |
| WO2023034837A2 (en) | 2021-08-31 | 2023-03-09 | Alnylam Pharmaceuticals, Inc. | Cell death-inducing dffa-like effector b (cideb) irna compositions and methods of use thereof |
| WO2023031394A1 (en) | 2021-09-03 | 2023-03-09 | CureVac SE | Novel lipid nanoparticles for delivery of nucleic acids |
| MX2024002725A (en) | 2021-09-03 | 2024-03-15 | CureVac SE | Novel lipid nanoparticles for delivery of nucleic acids comprising phosphatidylserine. |
| CN115772089B (en)* | 2021-09-07 | 2025-06-10 | 广州谷森制药有限公司 | Cationic lipid compounds |
| CA3232386A1 (en) | 2021-09-14 | 2023-03-23 | Renagade Therapeutics Management Inc. | Cyclic lipids and methods of use thereof |
| CA3231523A1 (en) | 2021-09-14 | 2023-03-23 | Renagade Therapeutics Management Inc. | Acyclic lipids and methods of use thereof |
| CN118234867A (en) | 2021-09-17 | 2024-06-21 | 旗舰创业创新六公司 | Compositions and methods for producing cyclic polyribonucleotides |
| JP2024536147A (en) | 2021-10-01 | 2024-10-04 | エーダーエックス ファーマシューティカルズ， インコーポレイテッド | Compositions and methods of use for modulating prekallikrein - Patent Application 20070123333 |
| KR20240126857A (en) | 2021-10-18 | 2024-08-21 | 플래그쉽 파이어니어링 이노베이션스 브이아이, 엘엘씨 | Compositions and methods for purifying polyribonucleotides |
| EP4422698A1 (en) | 2021-10-29 | 2024-09-04 | CureVac SE | Improved circular rna for expressing therapeutic proteins |
| WO2023076450A2 (en) | 2021-10-29 | 2023-05-04 | Alnylam Pharmaceuticals, Inc. | HUNTINGTIN (HTT) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF |
| US20250043269A1 (en) | 2021-11-03 | 2025-02-06 | The J. David Gladstone Institutes, a testamentary trust established under the Will of J. David Glad | Precise Genome Editing Using Retrons |
| TW202334080A (en) | 2021-11-08 | 2023-09-01 | 美商歐納醫療公司 | Lipid nanoparticle compositions for delivering circular polynucleotides |
| KR102772764B1 (en) | 2021-11-10 | 2025-02-27 | 주식회사 에스엠엘바이오팜 | A pharmaceutical composition of lipid nano particle for delivering nucleic acid drug comprising trehalose derivitive and novel structural lipid compound |
| KR20240122774A (en) | 2021-11-16 | 2024-08-13 | 세일 바이오메디슨스, 인크. | Novel ionizable lipids and lipid nanoparticles, and methods of using the same |
| KR20240128683A (en) | 2021-11-22 | 2024-08-26 | 세일 바이오메디슨스, 인크. | Novel ionizable lipids and lipid nanoparticles, and methods of using the same |
| CA3238735A1 (en) | 2021-11-24 | 2023-06-01 | Jennifer A. Nelson | Immunogenic compositions and their uses |
| JP2024541467A (en) | 2021-11-24 | 2024-11-08 | フラッグシップ パイオニアリング イノベーションズ シックス，エルエルシー | Coronavirus immunogenic compositions and their uses |
| MX2024006407A (en) | 2021-11-24 | 2024-08-19 | Flagship Pioneering Innovations Vi Llc | Varicella-zoster virus immunogen compositions and their uses. |
| US20250049714A1 (en)* | 2021-12-09 | 2025-02-13 | Massachusetts Institute Of Technology | Synthesis of ester, carbonate, and carbamate-derived novel biodegradable ionizable lipids from methyl ricinoleate or methyl 12-hydroxystearate and its applications |
| CN118647600A (en) | 2021-12-16 | 2024-09-13 | 爱康泰生治疗公司 | Lipids for lipid nanoparticle formulation |
| EP4448758A1 (en) | 2021-12-17 | 2024-10-23 | Flagship Pioneering Innovations VI, LLC | Methods for enrichment of circular rna under denaturing conditions |
| JP2025500360A (en) | 2021-12-22 | 2025-01-09 | フラッグシップ パイオニアリング イノベーションズ シックス，エルエルシー | Compositions and methods for purifying polyribonucleotides |
| TW202342064A (en) | 2021-12-23 | 2023-11-01 | 美商旗艦先鋒創新有限責任公司 | Circular polyribonucleotides encoding antifusogenic polypeptides |
| WO2023122752A1 (en) | 2021-12-23 | 2023-06-29 | Renagade Therapeutics Management Inc. | Constrained lipids and methods of use thereof |
| WO2023135273A2 (en) | 2022-01-14 | 2023-07-20 | Anjarium Biosciences Ag | Compositions of dna molecules encoding factor viii, methods of making thereof, and methods of use thereof |
| WO2023141602A2 (en) | 2022-01-21 | 2023-07-27 | Renagade Therapeutics Management Inc. | Engineered retrons and methods of use |
| WO2023141314A2 (en) | 2022-01-24 | 2023-07-27 | Alnylam Pharmaceuticals, Inc. | Heparin sulfate biosynthesis pathway enzyme irna agent compositions and methods of use thereof |
| WO2023144193A1 (en) | 2022-01-25 | 2023-08-03 | CureVac SE | Mrnas for treatment of hereditary tyrosinemia type i |
| WO2023147090A1 (en) | 2022-01-27 | 2023-08-03 | BioNTech SE | Pharmaceutical compositions for delivery of herpes simplex virus antigens and related methods |
| WO2023144330A1 (en) | 2022-01-28 | 2023-08-03 | CureVac SE | Nucleic acid encoded transcription factor inhibitors |
| JP2025508467A (en) | 2022-02-24 | 2025-03-26 | アイオー バイオテック エーピーエス | Nucleotide Delivery for Cancer Therapy |
| KR20240161965A (en) | 2022-03-14 | 2024-11-13 | 제너레이션 바이오 컴퍼니 | Heterologous Prime Boost Vaccine Composition and Method of Use |
| WO2023176821A1 (en) | 2022-03-15 | 2023-09-21 | 富士フイルム株式会社 | Lipid composition |
| JP2025510229A (en)* | 2022-03-25 | 2025-04-14 | セイル バイオメディシンズ インコーポレイテッド | Novel ionized lipids and lipid nanoparticles and methods of using them |
| CN114933569B (en)* | 2022-04-07 | 2024-07-23 | 澳门科技大学 | Sphingolipid compounds, liposomes containing sphingolipid compounds and applications |
| WO2023196931A1 (en) | 2022-04-07 | 2023-10-12 | Renagade Therapeutics Management Inc. | Cyclic lipids and lipid nanoparticles (lnp) for the delivery of nucleic acids or peptides for use in vaccinating against infectious agents |
| WO2023196634A2 (en) | 2022-04-08 | 2023-10-12 | Flagship Pioneering Innovations Vii, Llc | Vaccines and related methods |
| WO2023198828A1 (en) | 2022-04-13 | 2023-10-19 | Universitat Autònoma De Barcelona | Treatment of neuromuscular diseases via gene therapy that expresses klotho protein |
| AU2023269030A1 (en) | 2022-05-09 | 2024-11-14 | Flagship Pioneering Innovations Vi, Llc | Trem compositions and methods of use for treating proliferative disorders |
| WO2023220729A2 (en) | 2022-05-13 | 2023-11-16 | Flagship Pioneering Innovations Vii, Llc | Double stranded dna compositions and related methods |
| WO2023218420A1 (en) | 2022-05-13 | 2023-11-16 | Janssen Pharmaceuticals, Inc. | Mrna compositions for inducing latent hiv-1 reversal |
| IL316630A (en) | 2022-05-13 | 2024-12-01 | BioNTech SE | Rna compositions targeting hiv |
| CN117203186A (en)* | 2022-05-13 | 2023-12-08 | 南方科技大学 | Lipid compound containing disulfide bond and composition thereof |
| CN119947754A (en) | 2022-05-25 | 2025-05-06 | 旗舰创业创新第七有限责任公司 | Compositions and methods for modulating tumor suppressors and oncogenes |
| CN120035678A (en) | 2022-05-25 | 2025-05-23 | 旗舰创业创新第七有限责任公司 | Compositions and methods for modulating circulating factors |
| EP4531905A1 (en) | 2022-05-25 | 2025-04-09 | BioNTech SE | Rna compositions for delivery of monkeypox antigens and related methods |
| IL317109A (en) | 2022-05-25 | 2025-01-01 | Akagera Medicines Inc | Lipid nanoparticles for delivery of nucleic acids and methods of use thereof |
| CN119907687A (en) | 2022-05-25 | 2025-04-29 | 旗舰创业创新第七有限责任公司 | Compositions and methods for regulating cytokines |
| CN119563038A (en) | 2022-05-25 | 2025-03-04 | 旗舰创业创新七公司 | Compositions and methods for modulating immune responses |
| CN119212720A (en) | 2022-05-25 | 2024-12-27 | 库瑞瓦格欧洲股份公司 | Nucleic acid-based vaccines encoding Escherichia coli FimH antigenic polypeptides |
| KR20250021325A (en) | 2022-05-25 | 2025-02-12 | 플래그쉽 파이어니어링 이노베이션스 Vii, 엘엘씨 | Compositions and methods for modulating genetic factors |
| WO2023232747A1 (en) | 2022-05-30 | 2023-12-07 | BioNTech SE | Complexes for delivery of nucleic acids |
| WO2023239756A1 (en) | 2022-06-07 | 2023-12-14 | Generation Bio Co. | Lipid nanoparticle compositions and uses thereof |
| WO2023250112A1 (en) | 2022-06-22 | 2023-12-28 | Flagship Pioneering Innovations Vi, Llc | Compositions of modified trems and uses thereof |
| KR20250029913A (en) | 2022-07-29 | 2025-03-05 | 매사추세츠 인스티튜트 오브 테크놀로지 | Composition and method for inhibiting expression of signal regulatory protein alpha (SIRPα) gene |
| AU2023320333A1 (en) | 2022-08-01 | 2025-01-16 | Flagship Pioneering Innovations Vii, Llc | Immunomodulatory proteins and related methods |
| WO2024035952A1 (en) | 2022-08-12 | 2024-02-15 | Remix Therapeutics Inc. | Methods and compositions for modulating splicing at alternative splice sites |
| WO2024040222A1 (en) | 2022-08-19 | 2024-02-22 | Generation Bio Co. | Cleavable closed-ended dna (cedna) and methods of use thereof |
| CN120239693A (en) | 2022-08-31 | 2025-07-01 | 赛欧生物医药股份有限公司 | Novel ionizable lipids and lipid nanoparticles and methods of using the same |
| CN120152962A (en) | 2022-09-06 | 2025-06-13 | 国立大学法人九州大学 | Lipid Nanoparticles |
| WO2024063788A1 (en) | 2022-09-23 | 2024-03-28 | BioNTech SE | Compositions for delivery of malaria antigens and related methods |
| WO2024063789A1 (en) | 2022-09-23 | 2024-03-28 | BioNTech SE | Compositions for delivery of malaria antigens and related methods |
| WO2024064910A1 (en) | 2022-09-23 | 2024-03-28 | Chroma Medicine, Inc. | Compositions and methods for epigenetic regulation of hbv gene expression |
| WO2024064934A1 (en) | 2022-09-23 | 2024-03-28 | BioNTech SE | Compositions for delivery of plasmodium csp antigens and related methods |
| EP4590330A1 (en) | 2022-09-23 | 2025-07-30 | BioNTech SE | Compositions for delivery of liver stage antigens and related methods |
| CN119947747A (en) | 2022-09-26 | 2025-05-06 | 葛兰素史克生物有限公司 | Influenza virus vaccine |
| US20240174732A1 (en) | 2022-10-05 | 2024-05-30 | Flagship Pioneering Innovations V, Inc. | Nucleic acid molecules encoding trif and additional polypeptides and their use in treating cancer |
| WO2024074211A1 (en) | 2022-10-06 | 2024-04-11 | BioNTech SE | Rna compositions targeting claudin-18.2 |
| CN120129702A (en) | 2022-10-06 | 2025-06-10 | 生物技术公司 | RNA composition targeting claudin-18.2 |
| EP4608442A1 (en) | 2022-10-28 | 2025-09-03 | GlaxoSmithKline Biologicals S.A. | Nucleic acid based vaccine |
| CN120513299A (en) | 2022-10-31 | 2025-08-19 | 旗舰创业创新第六有限责任公司 | Compositions and methods for purifying polyribonucleotides |
| AR131008A1 (en) | 2022-11-08 | 2025-02-05 | Flagship Pioneering Innovations Vi Llc | COMPOSITIONS AND METHODS FOR PRODUCING CIRCULAR POLYRIBONUCLEOTIDES |
| TW202428289A (en) | 2022-11-08 | 2024-07-16 | 美商歐納醫療公司 | Circular rna compositions |
| WO2024102730A1 (en) | 2022-11-08 | 2024-05-16 | Orna Therapeutics, Inc. | Lipids and nanoparticle compositions for delivering polynucleotides |
| WO2024102762A1 (en) | 2022-11-08 | 2024-05-16 | Orna Therapeutics, Inc. | Lipids and lipid nanoparticle compositions for delivering polynucleotides |
| WO2024102954A1 (en) | 2022-11-10 | 2024-05-16 | Massachusetts Institute Of Technology | Activation induced clipping system (aics) |
| EP4626402A1 (en) | 2022-12-01 | 2025-10-08 | Generation Bio Co. | Lipid nanoparticles comprising nucleic acids and lipid-anchored polymers |
| CN120641085A (en) | 2022-12-01 | 2025-09-12 | 世代生物公司 | Lipid nanoparticles comprising nucleic acids, ionizable lipids, sterols, lipid anchoring polymers and helper lipids, uses thereof |
| IL320873A (en) | 2022-12-01 | 2025-07-01 | Generation Bio Co | Novel polyglycerol-conjugated lipids and lipid nanoparticle compositions comprising the same |
| KR20250114116A (en) | 2022-12-01 | 2025-07-28 | 제너레이션 바이오 컴퍼니 | Stealth lipid nanoparticle compositions for cell targeting |
| WO2024121814A1 (en) | 2022-12-09 | 2024-06-13 | Takeda Pharmaceutical Company Limited | Modified immunomodulators |
| EP4631528A1 (en) | 2022-12-09 | 2025-10-15 | Nibec Co., Ltd. | Nanoparticle comprising peptide-based conjugate for delivering oligonucleotide into target cell and pharmaceutical composition comprising same |
| WO2024123134A1 (en) | 2022-12-09 | 2024-06-13 | 서울대학교산학협력단 | Nanoparticle comprising peptide-based conjugate for delivering mrna into b cell and t cell and uses thereof |
| WO2024129988A1 (en) | 2022-12-14 | 2024-06-20 | Flagship Pioneering Innovations Vii, Llc | Compositions and methods for delivery of therapeutic agents to bone |
| WO2024141955A1 (en) | 2022-12-28 | 2024-07-04 | BioNTech SE | Rna compositions targeting hiv |
| WO2024151673A2 (en) | 2023-01-09 | 2024-07-18 | President And Fellows Of Harvard College | Recombinant nucleic acid molecules and their use in wound healing |
| TW202438673A (en) | 2023-01-09 | 2024-10-01 | 美商旗艦先鋒創新有限責任（Ｖｉｉ）公司 | Vaccines and related methods |
| WO2024151685A1 (en) | 2023-01-09 | 2024-07-18 | Beth Israel Deaconess Medical Center, Inc. | Recombinant nucleic acid molecules and their use in wound healing |
| US20240269251A1 (en) | 2023-01-09 | 2024-08-15 | Flagship Pioneering Innovations V, Inc. | Genetic switches and their use in treating cancer |
| CN120603811A (en) | 2023-01-27 | 2025-09-05 | 富士胶片株式会社 | Compound or its salt, lipid composition, pharmaceutical composition and delivery vector |
| WO2024160936A1 (en) | 2023-02-03 | 2024-08-08 | Glaxosmithkline Biologicals Sa | Rna formulation |
| US20240269263A1 (en) | 2023-02-06 | 2024-08-15 | Flagship Pioneering Innovations Vii, Llc | Immunomodulatory compositions and related methods |
| WO2024173307A2 (en) | 2023-02-13 | 2024-08-22 | Flagship Pioneering Innovation Vii, Llc | Cleavable linker-containing ionizable lipids and lipid carriers for therapeutic compositions |
| GB202302092D0 (en) | 2023-02-14 | 2023-03-29 | Glaxosmithkline Biologicals Sa | Analytical method |
| US20240285805A1 (en) | 2023-02-17 | 2024-08-29 | Flagship Pioneering Innovations Vii, Llc | Dna compositions comprising modified uracil |
| AU2024220221A1 (en) | 2023-02-17 | 2025-08-07 | Flagship Pioneering Innovations Vii, Llc | Dna compositions comprising modified cytosine |
| WO2024184500A1 (en) | 2023-03-08 | 2024-09-12 | CureVac SE | Novel lipid nanoparticle formulations for delivery of nucleic acids |
| WO2024192422A1 (en) | 2023-03-15 | 2024-09-19 | Flagship Pioneering Innovations Vi, Llc | Immunogenic compositions and uses thereof |
| AU2024235803A1 (en) | 2023-03-15 | 2025-09-25 | Flagship Pioneering Innovations Vi, Llc | Compositions comprising polyribonucleotides and uses thereof |
| WO2024205657A2 (en) | 2023-03-29 | 2024-10-03 | Orna Therapeutics, Inc. | Lipids and lipid nanoparticle compositions for delivering polynucleotides |
| WO2024200823A1 (en) | 2023-03-30 | 2024-10-03 | Ose Immunotherapeutics | Lipid-based nanoparticle targeted at activated immune cells for the expression of immune cell enhancing molecule and use thereof |
| WO2024200826A1 (en) | 2023-03-30 | 2024-10-03 | Ose Immunotherapeutics | Lipid-based nanoparticle targeted at activated immune cells for the expression of immune cell inhibiting molecule and use thereof |
| AR132276A1 (en) | 2023-04-07 | 2025-06-11 | Takeda Pharmaceuticals Co | CONJUGATION COMPLEX |
| WO2024216128A1 (en) | 2023-04-12 | 2024-10-17 | Flagship Pioneering Innovations Vi, Llc | Trems for use in correction of missense mutations |
| WO2024216191A1 (en) | 2023-04-12 | 2024-10-17 | Flagship Pioneering Innovations Vi, Llc | Modified trems, compositions, and related methods thereof |
| TW202448484A (en) | 2023-04-20 | 2024-12-16 | 美商雅迪克斯製藥公司 | Mapt-modulating compositions and methods of use thereof |
| WO2024220746A2 (en) | 2023-04-21 | 2024-10-24 | Flagship Pioneering Innovations Vii, Llc | Rnai agents targeting fatty acid synthase and related methods |
| WO2024223724A1 (en) | 2023-04-27 | 2024-10-31 | Glaxosmithkline Biologicals Sa | Influenza virus vaccines |
| WO2024223728A1 (en) | 2023-04-27 | 2024-10-31 | Glaxosmithkline Biologicals Sa | Influenza virus vaccines |
| US20240401025A1 (en) | 2023-05-03 | 2024-12-05 | Manifold Biotechnologies, Inc. | Methods and compositions for high-throughput protein delivery, screening, and detection |
| WO2024228150A1 (en) | 2023-05-03 | 2024-11-07 | BioNTech SE | Optimized csp variants and related methods |
| WO2024228044A1 (en) | 2023-05-03 | 2024-11-07 | BioNTech SE | Optimized csp variants and related methods |
| AU2024269222A1 (en) | 2023-05-05 | 2025-10-09 | Orna Therapeutics, Inc. | Circular rna compositions and methods |
| WO2024230934A1 (en) | 2023-05-11 | 2024-11-14 | CureVac SE | Therapeutic nucleic acid for the treatment of ophthalmic diseases |
| TW202502385A (en) | 2023-05-12 | 2025-01-16 | 美商雅迪克斯製藥公司 | Nmda ligand conjugated compounds and uses thereof |
| DE102023001946A1 (en) | 2023-05-12 | 2024-11-14 | Friedrich-Schiller-Universität Jena, Körperschaft des öffentlichen Rechts | Nanoparticles for the transport of active substances with anionic groups, processes for their preparation and their use |
| WO2024236361A1 (en) | 2023-05-15 | 2024-11-21 | Takeda Pharmaceutical Company Limited | Compositions and methods for delivery of nucleic acids to cells |
| WO2024238700A1 (en) | 2023-05-15 | 2024-11-21 | Chroma Medicine, Inc. | Compositions and methods for epigenetic regulation of hbv gene expression |
| US20240382622A1 (en) | 2023-05-15 | 2024-11-21 | Chroma Medicine, Inc. | Compositions and methods for epigenetic regulation of hbv gene expression |
| WO2024236504A1 (en) | 2023-05-15 | 2024-11-21 | Takeda Pharmaceutical Company Limited | Sequences and methods for delivery of dna and rna |
| WO2024238981A1 (en)* | 2023-05-18 | 2024-11-21 | Vycellix, Inc. | Plasma membrane embedded system for spaciotemporal controlled payload delivery of biologics |
| US20240390284A1 (en)* | 2023-05-25 | 2024-11-28 | Bristol-Myers Squibb Company | Ionizable lipids |
| WO2024249328A2 (en) | 2023-05-26 | 2024-12-05 | Adarx Pharmaceuticals, Inc. | Sod1-modulating compositions and methods of use thereof |
| WO2024251108A1 (en)* | 2023-06-07 | 2024-12-12 | 北京因诺惟康医药科技有限公司 | Ionizable lipid compound, lipid carrier comprising same and use thereof |
| WO2024258829A1 (en) | 2023-06-12 | 2024-12-19 | Flagship Pioneering Innovations Vii, Llc | Sars-cov-2 vaccine compositions and related methods |
| WO2024263694A1 (en) | 2023-06-20 | 2024-12-26 | Adarx Pharmaceuticals, Inc. | Lrrk2-modulating compositions and methods of use thereof |
| WO2025006684A1 (en) | 2023-06-28 | 2025-01-02 | Flagship Pioneering Innovations Vi, Llc | Circular polyribonucleotides encoding antifusogenic polypeptides |
| WO2025008774A1 (en) | 2023-07-05 | 2025-01-09 | Takeda Pharmaceutical Company Limited | Viral vectors encoding recombinant fviii variants with increased expression for gene therapy of hemophilia a |
| TW202515531A (en) | 2023-07-07 | 2025-04-16 | 美商輝瑞股份有限公司 | Amphiphilic tlr7/8 adjuvants and uses thereof |
| WO2025011529A2 (en) | 2023-07-07 | 2025-01-16 | Shanghai Circode Biomed Co., Ltd. | Circular rna vaccines for seasonal flu and methods of uses |
| WO2025024335A2 (en) | 2023-07-21 | 2025-01-30 | BioNTech SE | Compositions for delivery of plasmodium antigens and related methods |
| WO2025024324A1 (en) | 2023-07-21 | 2025-01-30 | BioNTech SE | Compositions for delivery of plasmodium antigens and related methods |
| WO2025024337A1 (en) | 2023-07-24 | 2025-01-30 | BioNTech SE | Compositions for delivery of plasmodium antigens and related methods |
| US20250092426A1 (en) | 2023-07-25 | 2025-03-20 | Flagship Pioneering Innovations Vii, Llc | Cas endonucleases and related methods |
| WO2025026545A1 (en) | 2023-08-01 | 2025-02-06 | BioNTech SE | Ionizable thioplipids and uses thereof |
| WO2025027116A1 (en) | 2023-08-01 | 2025-02-06 | Institut Curie | Nanoparticles comprising nucleic acid sequences encoding cyclic gmp-amp synthase |
| TW202519509A (en) | 2023-08-01 | 2025-05-16 | 德商拜恩技術股份公司 | Ionizable thiolipids and uses thereof |
| WO2025030154A1 (en) | 2023-08-03 | 2025-02-06 | The Trustees Of The University Of Pennsylvania | Pharmaceutical compositions for delivery of herpes simplex virus glycoprotein b antigens and related methods |
| WO2025027576A2 (en) | 2023-08-03 | 2025-02-06 | BioNTech SE | Rna compositions targeting hiv |
| WO2025030097A2 (en) | 2023-08-03 | 2025-02-06 | BioNTech SE | Pharmaceutical compositions for delivery of herpes simplex virus antigens and related methods |
| WO2025027579A2 (en) | 2023-08-03 | 2025-02-06 | BioNTech SE | Rna compositions targeting hiv |
| WO2025042786A1 (en) | 2023-08-18 | 2025-02-27 | Flagship Pioneering Innovations Vi, Llc | Compositions comprising circular polyribonucleotides and uses thereof |
| WO2025045142A1 (en) | 2023-08-29 | 2025-03-06 | Shanghai Circode Biomed Co., Ltd. | Circular rna encoding vegf polypeptides, formulations, and methods of uses |
| WO2025049690A1 (en) | 2023-08-29 | 2025-03-06 | Orna Therapeutics, Inc. | Circular polyethylene glycol lipids |
| WO2025054236A2 (en) | 2023-09-06 | 2025-03-13 | Flagship Pioneering Innovations Vii, Llc | Sars-cov-2 vaccine compositions and related methods |
| WO2025054556A1 (en) | 2023-09-07 | 2025-03-13 | BioNTech SE | Rna compositions for delivery of mpox antigens and related methods |
| WO2025052180A2 (en) | 2023-09-07 | 2025-03-13 | Axelyf ehf. | Lipids and lipid nanoparticles |
| WO2025056938A1 (en) | 2023-09-11 | 2025-03-20 | BioNTech SE | Rna compositions for delivery of incretin agents |
| WO2025057088A1 (en) | 2023-09-11 | 2025-03-20 | BioNTech SE | Rna compositions for delivery of incretin agents |
| WO2025064475A2 (en) | 2023-09-18 | 2025-03-27 | Flagship Pioneering Innovations Vii, Llc | Ionizable lipidoid compositions and therapeutic uses thereof |
| WO2025064591A1 (en)* | 2023-09-19 | 2025-03-27 | The Regents Of The University Of California | In vivo gene editing of tau locus via liponanoparticle delivery |
| WO2025064850A1 (en) | 2023-09-22 | 2025-03-27 | BioNTech SE | Rna constructs with n-terminal degrons to enhance an immune response |
| WO2025072331A1 (en) | 2023-09-26 | 2025-04-03 | Flagship Pioneering Innovations Vii, Llc | Cas nucleases and related methods |
| WO2025081042A1 (en) | 2023-10-12 | 2025-04-17 | Renagade Therapeutics Management Inc. | Nickase-retron template-based precision editing system and methods of use |
| WO2025096807A2 (en) | 2023-10-31 | 2025-05-08 | Flagship Pioneering Innovations Vii, Llc | Novel therapeutic dna forms |
| WO2025101501A1 (en) | 2023-11-07 | 2025-05-15 | Orna Therapeutics, Inc. | Circular rna compositions |
| US20250162981A1 (en) | 2023-11-14 | 2025-05-22 | Flagship Pioneering Innovations Vii, Llc | Ionizable lipidoid compositions and therapeutic uses thereof |
| WO2025106754A1 (en) | 2023-11-15 | 2025-05-22 | BioNTech SE | Coronavirus vaccine |
| TW202523695A (en) | 2023-11-22 | 2025-06-16 | 美商旗艦先鋒創新有限責任（Ｖｉｉ）公司 | Methods and compositions for treating non-alcoholic fatty liver disease |
| WO2025117877A2 (en) | 2023-12-01 | 2025-06-05 | Flagship Pioneering Innovations Vii, Llc | Cas nucleases and related methods |
| WO2025124711A1 (en) | 2023-12-13 | 2025-06-19 | BioNTech SE | Glycolipid compositions |
| WO2025132839A1 (en) | 2023-12-21 | 2025-06-26 | Glaxosmithkline Biologicals Sa | Influenza virus vaccines |
| WO2025133105A1 (en) | 2023-12-21 | 2025-06-26 | Biontech Delivery Technologies Gmbh | Compositions and methods |
| WO2025134066A1 (en) | 2023-12-21 | 2025-06-26 | Biontech Delivery Technologies Gmbh | Ionizable lipids |
| TW202525287A (en) | 2023-12-21 | 2025-07-01 | 德商拜恩技術運輸科技有限責任公司 | Ionizable lipids |
| WO2025133115A1 (en) | 2023-12-21 | 2025-06-26 | Ose Immunotherapeutics | Lipid-based nanoparticles comprising il-35 |
| WO2025149492A1 (en) | 2024-01-08 | 2025-07-17 | BioNTech SE | Rna encoding an immune inhibitory il-1 family member |
| WO2025155753A2 (en) | 2024-01-17 | 2025-07-24 | Renagade Therapeutics Management Inc. | Improved gene editing system, guides, and methods |
| WO2025160334A1 (en) | 2024-01-26 | 2025-07-31 | Flagship Pioneering Innovations Vii, Llc | Immunoreceptor inhibitory proteins and related methods |
| WO2025157978A1 (en)* | 2024-01-26 | 2025-07-31 | Merck Patent Gmbh | Ionizable lipids for use in lipid nanoparticles |
| WO2025166323A2 (en) | 2024-02-02 | 2025-08-07 | Editas Medicine, Inc. | Crispr-related methods and compositions targeting lipoprotein (a) expression |
| WO2025180874A1 (en)* | 2024-02-27 | 2025-09-04 | Basf Se | Substituted 1,3-dioxolane sulfates and their use |
| WO2025184508A1 (en) | 2024-03-01 | 2025-09-04 | Acuitas Therapeutics, Inc. | Materials and methods for encapsulating therapeutics in lipid nanoparticles |
| WO2025194019A1 (en) | 2024-03-14 | 2025-09-18 | Flagship Pioneering Innovations Vii, Llc | Methods for treating liver fibrosis and non-alcoholic fatty liver disease |
| WO2025202937A1 (en) | 2024-03-26 | 2025-10-02 | BioNTech SE | Cancer vaccines |
| GB202404607D0 (en) | 2024-03-29 | 2024-05-15 | Glaxosmithkline Biologicals Sa | RNA formulation |